HK1019404A1 - Injection formulations of avermectins or milbemycins based on castor oil, their preparation, and use of castor for preparing the same - Google Patents

Injection formulations of avermectins or milbemycins based on castor oil, their preparation, and use of castor for preparing the same

Info

Publication number
HK1019404A1
HK1019404A1 HK99104544A HK99104544A HK1019404A1 HK 1019404 A1 HK1019404 A1 HK 1019404A1 HK 99104544 A HK99104544 A HK 99104544A HK 99104544 A HK99104544 A HK 99104544A HK 1019404 A1 HK1019404 A1 HK 1019404A1
Authority
HK
Hong Kong
Prior art keywords
castor
avermectins
preparing
preparation
same
Prior art date
Application number
HK99104544A
Other languages
English (en)
Inventor
Michael Grosse-Bley
Richard Kujanek
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7790774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1019404(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of HK1019404A1 publication Critical patent/HK1019404A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK99104544A 1996-04-09 1999-10-14 Injection formulations of avermectins or milbemycins based on castor oil, their preparation, and use of castor for preparing the same HK1019404A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19613972A DE19613972A1 (de) 1996-04-09 1996-04-09 Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
PCT/EP1997/001569 WO1997037653A1 (fr) 1996-04-09 1997-03-27 Formulations a injecter d'avermectines et de milbemycines a base d'huile de ricin

Publications (1)

Publication Number Publication Date
HK1019404A1 true HK1019404A1 (en) 2000-02-11

Family

ID=7790774

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99104544A HK1019404A1 (en) 1996-04-09 1999-10-14 Injection formulations of avermectins or milbemycins based on castor oil, their preparation, and use of castor for preparing the same

Country Status (14)

Country Link
US (1) US6063394A (fr)
EP (1) EP0896534B1 (fr)
JP (1) JP4257870B2 (fr)
CN (1) CN1095662C (fr)
AT (1) ATE285233T1 (fr)
AU (1) AU718807B2 (fr)
BR (1) BR9708540B1 (fr)
CA (1) CA2251087C (fr)
DE (2) DE19613972A1 (fr)
ES (1) ES2235230T3 (fr)
HK (1) HK1019404A1 (fr)
NZ (1) NZ332224A (fr)
PT (1) PT896534E (fr)
WO (1) WO1997037653A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19638045A1 (de) * 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
BR9815352A (pt) * 1997-12-03 2000-10-17 Merck & Co Inc "formulação injetável de longa ação, e, processos para a prevenção ou tratamento de infestação parasìtica em um hospedeiro em necessidade dele, para tratamento ou prevenção de infestação por insetos por um perìodo prolongado de tempo em um hospedeiro em necessidade dele, para promover crescimento em animais, e para tratar inflamação, dor ou febre por um perìodo estendido de tempo em um hospedeiro em necessidade. "
US6174540B1 (en) 1998-09-14 2001-01-16 Merck & Co., Inc. Long acting injectable formulations containing hydrogenated caster oil
GB9827727D0 (en) * 1998-12-16 1999-02-10 Pfizer Ltd Antiparasitic formulations
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
AU781682B2 (en) * 2000-03-20 2005-06-09 Zoetis Services Llc Sustained-release compositions for parenteral administration
US20050009762A1 (en) * 2003-06-06 2005-01-13 Strobel Michael Albert Application of water and organic solvent soluble ivermectin for topical and oral use
CN1275589C (zh) * 2002-05-31 2006-09-20 王玉万 含抗寄生虫药物的缓释注射剂
US7262214B2 (en) 2003-02-26 2007-08-28 Merial Limited 1-N-arylpyrazole derivatives in prevention of arthropod-borne and mosquito-borne diseases
US20050271459A1 (en) * 2004-06-03 2005-12-08 World Wide Stationery Mfg. Co., Ltd. Interlocking ring tip formations for paired ring members of a ring binder mechanism
NZ534939A (en) * 2004-08-26 2007-04-27 Bomac Research Ltd Injectable formulation comprising an anthelmintic compound with complexing compound for improved solubility
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
EP2194965B1 (fr) * 2007-08-31 2016-07-20 Archimedes Development Limited Compositions pharmaceutiques non aqueuses
NZ590141A (en) * 2008-06-24 2012-05-25 Merial Ltd Anthelminthic formulations including castor oil and another vegetable oil
PL2396006T3 (pl) 2009-02-16 2013-06-28 Zoetis Llc Preparat zawierający doramektynę w dużej dawce
CN101773467B (zh) * 2010-01-20 2015-09-09 北京大北农动物保健科技有限责任公司 一种美贝霉素或美贝霉素肟的兽用缓释注射液及制备方法
KR101805087B1 (ko) * 2010-09-16 2017-12-05 주식회사 엘지화학 높은 방부력을 제공하는 오일 주사 제형
AU2013201479C1 (en) * 2012-03-13 2017-11-09 Elanco New Zealand Long Acting Compositions
RU2020122841A (ru) 2017-12-15 2022-01-18 Тарсус Фармасьютикалс, Инк. Изоксазолиновые паразитицидные составы и способы лечения блефарита
US11077134B1 (en) 2020-11-10 2021-08-03 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
US11638714B2 (en) 2020-11-10 2023-05-02 Mountain Valley Md Inc Water dissolvable macrocyclic lactone cyclodextrin complexes
CN114642632A (zh) * 2022-02-25 2022-06-21 河北科技大学 一种莫西克汀注射液及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4914624A (fr) * 1972-06-08 1974-02-08
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
OA06863A (fr) * 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
NZ210505A (en) * 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
DE3727648A1 (de) * 1987-08-19 1989-03-02 Bayer Ag Neue avermectin derivate, verfahren zu ihrer herstellung und ihre verwendung
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
ES2052173T3 (es) * 1989-04-11 1994-07-01 Pfizer Composiciones inyectables que contienen 25-cyclohexil-avermectina b1.
NZ234802A (en) * 1989-08-14 1992-11-25 Merck & Co Inc Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
ES2086022T3 (es) * 1991-07-23 1996-06-16 American Cyanamid Co Composiciones estables para administracion parenteral y su uso.
ATE180671T1 (de) * 1991-09-30 1999-06-15 Merck & Co Inc Hydrierte rizinusöl-enthaltende injizierbare formulierungen mit verlängerter wirkstoffabgabe
AU5330294A (en) * 1992-10-21 1994-05-09 Micro Vesicular Systems, Inc. Entrapment vehicle and method

Also Published As

Publication number Publication date
EP0896534A1 (fr) 1999-02-17
BR9708540B1 (pt) 2010-07-27
CA2251087A1 (fr) 1997-10-16
WO1997037653A1 (fr) 1997-10-16
JP2000508301A (ja) 2000-07-04
DE59712134D1 (de) 2005-01-27
BR9708540A (pt) 1999-08-03
CN1095662C (zh) 2002-12-11
ES2235230T3 (es) 2005-07-01
CA2251087C (fr) 2008-01-15
ATE285233T1 (de) 2005-01-15
CN1215331A (zh) 1999-04-28
NZ332224A (en) 2000-06-23
AU2506697A (en) 1997-10-29
PT896534E (pt) 2005-04-29
US6063394A (en) 2000-05-16
JP4257870B2 (ja) 2009-04-22
AU718807B2 (en) 2000-04-20
DE19613972A1 (de) 1997-10-16
EP0896534B1 (fr) 2004-12-22

Similar Documents

Publication Publication Date Title
HK1019404A1 (en) Injection formulations of avermectins or milbemycins based on castor oil, their preparation, and use of castor for preparing the same
AU4308397A (en) Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors
AU3897197A (en) Substituted pyridines and biphenyls as anti-hypercholesterinemic, anti-hyperlipoproteinemic and anti-hyperglycemic agents
GR3036548T3 (en) Apparatus and method for preparing solid forms with controlled release of the active ingredient
AU6564794A (en) Use of nona- and decapeptides in the preparation of a drug for the treatment of aids
AU5833994A (en) Pharmaceutical and dermocosmetic compositions containing equine colostrum
BG103384A (en) Halogenpyrimidinylaryl (thio)ethers as pesticides
ZA978352B (en) Injection formulations of avermectins and milbemycins.
AU5648496A (en) Pyrazolo-(1,5a)pyrimidines, their preparation and their use
IL122737A0 (en) Salts of amidine derivative and cyclooxygenase inhibitors their preparation and pharmaceutical compositions containing them
GB2288183B (en) Composition and method of preparing microemulsion blends
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU3066697A (en) 8-hydrocarbyl substituted benzodizocine derivatives, their preparation and the ir use as protein kinase c (=pkc) modulators
ZA989664B (en) 3-substituted tetrahydropyrimidinone derivatives, their preparation and use.
MY127474A (en) Naphthyl compounds, intermediates, compositions, and methods of use
HK1002658A1 (en) Imidazopyridine-azolidinones their preparation and pharmaceutical use
UA48245C2 (uk) ЗАМІЩЕНІ 1,2,3,4-ТЕТРАГІДРО-2-ДИБЕНЗОФУРАНАМІНИ ТА 2-АМІНОЦИКЛОГЕПТА[B]БЕНЗОФУРАНИ, ФАРМАЦЕВТИЧНА ЛІКАРСЬКА ФОРМА ТА СПОСІБ ПІДВИЩЕННЯ АКТИВАЦІЇ 5-НТ<sub>1F</sub> РЕЦЕПТОРА У ССАВЦЯ
CA2151123A1 (fr) Cellules modifiees au niveau du catabolisme de la betaine, preparation et utilisations, notamment pour la production de metabolites ou d'enzymes
ZA976619B (en) Benzimidazole derivatives, their preparation and their therapeutic applications.
ZA989571B (en) 2-Substituted 1,2-Benzoisonthiazole derivatives, their preparation and use.
AU6646094A (en) New pyridinium salts and their use for controlling helicobacter bacteria
HK1036070A1 (en) 5-imino-13-deoxy anthracycline derivatives, their uses and processes for preparing them.
AP2000001746A0 (en) Anti- first-pass effect compounds.
AU2025997A (en) Novel heterocyclically substituted imidazoloquinoxalinones, their preparation and their use
AU5870298A (en) 1,4-dihydropyridin derivatives and their use in therapy

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20170326